HIV, soppressione virale mantenuta fino a 148 settimane con dolutegravir/rilpivirina
Sign up for free
Listen to this episode and many more. Enjoy the best podcasts on Spreaker!
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
Durante il congresso CROI2020 (Conference on Retroviruses and Opportunistic Infections) sono stati presentati nuovi dati derivanti da due trial di fase 3, gli studi SWORD. Questi risultati sottolineano che il...
show moreInformation
Author | PharmaStar |
Organization | PharmaStar |
Website | - |
Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company